PE20001463A1 - Nuevos derivados de piperidina, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados de piperidina, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
PE20001463A1
PE20001463A1 PE2000000102A PE0001022000A PE20001463A1 PE 20001463 A1 PE20001463 A1 PE 20001463A1 PE 2000000102 A PE2000000102 A PE 2000000102A PE 0001022000 A PE0001022000 A PE 0001022000A PE 20001463 A1 PE20001463 A1 PE 20001463A1
Authority
PE
Peru
Prior art keywords
piperidine
procedure
preparation
ilo
ethyl
Prior art date
Application number
PE2000000102A
Other languages
English (en)
Inventor
Jean Philippe Ducoux
Xavier Emonds-Alt
Patrick Gueule
Vincenzo Proietto
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9901593A external-priority patent/FR2789389B3/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of PE20001463A1 publication Critical patent/PE20001463A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIPERIDINA DE FORMULA I, DONDE X ES R2-N, R2-CH; Ar ES FENILO, ALQUILO C1-C3; R1 ES Cl, Br, ALQUILO C1-C3, TRIFLUOROMETILO; R2 ES CR3R4CONR5R6; R3 Y R4 SON METILO, ETILO, n-PROPILO, n-BUTILO; O JUNTO CON C FORMAN UN CICLOALQUILO C3-C6; R5 Y R6 SON H, ALQUILO C1-C3; O JUNTO CON N FORMAN UN HETEROCICLO TAL COMO ACETIDIN-1-ILO, PIRROLIDIN-1-ILO, PIPERIDIN-1-ILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 3-[2-[4-(1-CARBAMOIL-1-METILETIL)PIPERIDIN-1-IL]ETIL]-3-(3,4-DICLOROFENIL)-1-[2-(3,5-DIMETILFENIL)ACETIL]PIPERIDINA, 3-[2-[4-(1-N,N-DIMETILCARBAMOIL-1-METILETIL)PIPERACIN-1-IL]ETIL]-3-(3,4-DICLOROFENIL)-1-[2-(3,5-DIMETILFENIL)ACETIL]PIPERIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A LOS COMPUESTOS INTERMEDIOS Y A UNA COMPOSICION QUE UTILIZA DE 0,1 mg A 1000 mg DE PRINCIPIO ACTIVO. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR NK1 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE PATOLOGIAS DEL SISTEMA RESPIRATORIO, GASTROINTESTINAL, URINARIO, INMUNITARIO, CARDIOVASCULAR, SISTEMA NERVIOSO CENTRAL, DOLOR, MIGRANA, INFLAMACION
PE2000000102A 1999-02-10 2000-02-10 Nuevos derivados de piperidina, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen PE20001463A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9901593A FR2789389B3 (fr) 1999-02-10 1999-02-10 Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR9904429A FR2789390B3 (fr) 1999-02-10 1999-04-07 Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
PE20001463A1 true PE20001463A1 (es) 2001-02-21

Family

ID=26234812

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000102A PE20001463A1 (es) 1999-02-10 2000-02-10 Nuevos derivados de piperidina, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen

Country Status (37)

Country Link
US (2) US6642233B1 (es)
EP (1) EP1150970B1 (es)
JP (1) JP4648544B2 (es)
KR (1) KR100611261B1 (es)
CN (1) CN1273463C (es)
AR (1) AR028813A1 (es)
AT (1) ATE370942T1 (es)
AU (1) AU763716B2 (es)
BG (1) BG65031B1 (es)
BR (1) BR0008067A (es)
CA (1) CA2360894C (es)
CO (1) CO4980896A1 (es)
CZ (1) CZ300765B6 (es)
DE (1) DE60036081T2 (es)
DK (1) DK1150970T3 (es)
EE (1) EE04437B1 (es)
ES (1) ES2291187T3 (es)
FR (1) FR2789390B3 (es)
HK (1) HK1038927A1 (es)
HR (1) HRP20010566A2 (es)
HU (1) HUP0201281A3 (es)
ID (1) ID29219A (es)
IL (2) IL144363A0 (es)
ME (1) MEP11908A (es)
NO (2) NO321149B1 (es)
NZ (1) NZ513053A (es)
PE (1) PE20001463A1 (es)
PL (1) PL198561B1 (es)
PT (1) PT1150970E (es)
RS (1) RS50210B (es)
RU (1) RU2220956C2 (es)
SI (1) SI1150970T1 (es)
SK (1) SK286401B6 (es)
TR (1) TR200102331T2 (es)
TW (1) TWI254712B (es)
UA (1) UA70986C2 (es)
WO (1) WO2000047572A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217535A1 (en) * 2002-02-20 2003-09-09 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
US20050009798A1 (en) * 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
MXPA06008648A (es) * 2004-01-30 2006-09-04 Pfizer Prod Inc Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion.
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
GB2452696B (en) * 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
DE102008015425A1 (de) * 2008-03-20 2010-01-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen zur Verringerung von Juckreiz und anderen dermatologischen Missempfindungen, die insbesondere bei Altershaut auftreten können, mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid
DE102008015428A1 (de) * 2008-03-20 2009-09-24 Beiersdorf Ag Kühlende Zubereitungen für den humanen Haut- und/oder Schleimhautkontakt mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid
DE102008015426A1 (de) * 2008-03-20 2009-09-24 Beiersdorf Ag Kühlende kosmetische oder dermatologische Zubereitungen mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridyn-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid zu Reduktion von Hautrötungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US512901A (en) * 1894-01-16 Folding bed
GB821012A (en) * 1957-01-15 1959-09-30 Rhone Poulenc Sa New phenthiazine derivatives and processes for their preparation
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
CN1067385C (zh) 1994-08-25 2001-06-20 默里尔药物公司 用于治疗变应性疾病的新的取代的哌啶类化合物
CA2162786A1 (en) * 1994-11-22 1996-05-23 Philip Arthur Hipskind Heterocyclic tachykinin receptor antagonists

Also Published As

Publication number Publication date
IL180579A0 (en) 2007-06-03
SK286401B6 (sk) 2008-09-05
CN1345317A (zh) 2002-04-17
HRP20010566A2 (en) 2002-08-31
US6642233B1 (en) 2003-11-04
RS50210B (sr) 2009-07-15
US20040072840A1 (en) 2004-04-15
NO20013878L (no) 2001-10-10
NO20013878D0 (no) 2001-08-08
JP2002536442A (ja) 2002-10-29
HUP0201281A2 (en) 2002-09-28
CO4980896A1 (es) 2000-11-27
CA2360894A1 (en) 2000-08-17
SI1150970T1 (sl) 2008-02-29
ID29219A (id) 2001-08-16
YU56401A (sh) 2004-03-12
US6951940B2 (en) 2005-10-04
EE200100417A (et) 2002-12-16
EP1150970B1 (fr) 2007-08-22
ES2291187T3 (es) 2008-03-01
KR100611261B1 (ko) 2006-08-10
RU2220956C2 (ru) 2004-01-10
KR20010101818A (ko) 2001-11-14
DE60036081T2 (de) 2008-05-15
MEP11908A (en) 2010-06-10
HK1038927A1 (en) 2002-04-04
DE60036081D1 (de) 2007-10-04
IL144363A0 (en) 2002-05-23
FR2789390B3 (fr) 2001-03-09
NO20051958L (no) 2001-10-10
BG105794A (en) 2002-05-31
HUP0201281A3 (en) 2003-05-28
ATE370942T1 (de) 2007-09-15
SK11392001A3 (sk) 2002-02-05
FR2789390A1 (fr) 2000-08-11
PT1150970E (pt) 2007-11-07
BG65031B1 (bg) 2006-12-29
AU763716B2 (en) 2003-07-31
CZ20012888A3 (cs) 2001-11-14
EP1150970A1 (fr) 2001-11-07
JP4648544B2 (ja) 2011-03-09
PL198561B1 (pl) 2008-06-30
WO2000047572A1 (fr) 2000-08-17
TR200102331T2 (tr) 2002-03-21
TWI254712B (en) 2006-05-11
PL350243A1 (en) 2002-12-02
NO321149B1 (no) 2006-03-27
CN1273463C (zh) 2006-09-06
CA2360894C (en) 2009-09-22
AU2553100A (en) 2000-08-29
UA70986C2 (uk) 2004-11-15
EE04437B1 (et) 2005-02-15
CZ300765B6 (cs) 2009-08-05
DK1150970T3 (da) 2007-12-17
AR028813A1 (es) 2003-05-28
BR0008067A (pt) 2001-11-06
NZ513053A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
ES2549087T3 (es) Derivados de aminodihidrotiazina como inhibidores de BACE para el tratamiento de la enfermedad de Alzheimer
PE20081378A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
RU2342383C2 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
NO20072116L (no) Farmasoytiske forbindelser
RU2006124518A (ru) Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина
RU97108980A (ru) Производные бензимидазола, антигистаминовая фармацевтическая композиция и способ лечения аллергических заболеваний
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
RU2006135927A (ru) Бифенильные соединения, полезные в качестве антагонистов мускариновых рецепторов
UY29389A1 (es) Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones.
RU2005132616A (ru) Производные 2-фенокси и 2-фенилсульфонамида с ссr3 антагонистической активностью для лечения астмы и других воспалительных или иммунологических заболеваний
AR041302A1 (es) Compuestos de imidazopiridina como agonistas del receptor 5- ht4 y composiciones farmaceuticas que comprenden dichos compuestos
PE20020602A1 (es) Derivados de fenilcetona sustituidos como antagonistas del receptor de prostaglandina i2 (ip)
WO2007039781A3 (en) 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
PE20040698A1 (es) Derivados de isoindolina
PE20050460A1 (es) COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
TR200102789T2 (tr) Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
PE20001463A1 (es) Nuevos derivados de piperidina, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen
DK1157998T3 (da) Heterocykliske forbindelser, mellemprodukter derfor og elastaseinhibitorer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal